Atlas Trials

Study of Nivolumab in Combination With 177Lu-girentuximab for Kidney Cancer

Clinical trial NCT05239533 · ACTIVE_NOT_RECRUITING

Trial details

NCT number
NCT05239533
Sponsor
Memorial Sloan Kettering Cancer Center
Status
ACTIVE_NOT_RECRUITING
Phase
Phase 2
Study type
INTERVENTIONAL
Clear Cell Renal Cell CarcinomaKidney CancerAdvanced Renal Cell Carcinoma
Start date
2022-02-16
Primary completion
2027-03-01
Enrollment
9

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.